Chlorpyrifos (CPF) is an organophosphorus insecticide, acaricide, and miticide currently used to control insect pests on a variety of food and feed crops, most commonly corn. Prior to June 2000, CPF was also widely used for indoor pest control and pet collars, but most household uses were phased out beginning in June 2000 and canceled by January 2001 ([@R34]; [@R1]). Therefore, the primary route of exposure to the general U.S. population of children and adults today is dietary, and such exposure has been estimated to be approximately 0.15--0.32 μg/kg-d for acute dietary food-only exposure and 8--34 ng/kg-d for chronic dietary food exposure with food handling establishment uses (U.S. EPA b). Children and adults, including pregnant females, who are farm workers or living on or near farms may be exposed through additional pathways, including dermal or inhalation routes.

CPF and other organophosphates (OP) are currently regulated based on red blood cell (RBC) or brain acetylcholinesterase (AChE) inhibition; the latter is considered to be a primary mode of action for toxicity, especially related to the acute clinical signs of neurotoxicity following short-term high-dose exposures. Other modes of action for acute toxicity have also been proposed, including alterations of presynaptic cholinergic functions or noncholinergic neurochemical processes that may contribute to differential expression of toxicity among different OP ([@R19]; [@R27]; [@R32]). Young rats are more sensitive to acute effects of CPF than adults, and these differences may be attributable, in part, to age differences in metabolic enzymatic activity, especially at higher doses ([@R12]; [@R31]). Plasma butyrylcholinesterase (BuChE) inhibition may occur at exposure levels below those that provide brain or RBC AChE inhibition and is used as a marker of exposure in occupational settings.

Human and mechanistic animal studies have led to the hypothesis that developmental effects occur at subclinical exposure levels by mechanisms other than AChE inhibition ([@R29]). [@R30] stated that the fact that prenatal effects are elicited at "exposures below the threshold for inhibition of fetal brain cholinesterase reinforces the importance of other mechanisms underlying the developmental neurotoxicity of CPF, and potentially of other OP, and points to the inadequacy of cholinesterase activity as the sole factor for assessing exposure or safety" (426).

Therefore, a systematic evaluation of human and animal developmental studies is needed, including comparisons with AChE inhibition. Careful consideration of all developmental outcomes is important in providing the scientific basis for risk assessment, including science policy decisions required by the U.S. Environmental Protection Agency (EPA) Food Quality Protection Act (FQPA), which requires special protections for infants and children. A companion paper focuses on the developmental neurobehavioral data on CPF ([@R18]). This review focuses on epidemiologic studies that evaluated associations between CPF exposure and growth indices, including birth weight, birth length, and head circumference. This review assesses the evidence for and against a causal relationship between CPF exposure, as measured in umbilical cord blood, urinary metabolites, or air monitoring samples, and these outcomes.

The human data for growth indices are of interest because analyses were reported for birth outcomes before and after cancelation of residential uses and included data based on personal maternal monitoring of CPF exposures. In addition, this review evaluates whether the PON1 genotype, associated with detoxification of the toxic metabolite chlorpyrifos oxon (CPO), can modify associations between CPF exposure and fetal growth. Finally, the human data were compared with animal data for similar outcomes from developmental or reproductive animal studies published in the literature that include at least 3 CPF dose levels and 20 litters/dose group, which are the standard requirements fordevel-opmental toxicity studies based on the U.S. EPA Guidelines for Developmental Toxicity Risk Assessment ([@R28]).

The present review of the animal and epidemiologic studies on birth and growth outcomes differs from previous reviews ([@R8]; [@R12]; Weselak et al. 1999b; [@R38]; [@R45]; [@R44];) by contributing in-depth analyses of outcomes and including an additional study published in 2010 ([@R3]). The two 1999 expert panel reports ([@R8]; [@R9]) were written prior to publication of the epidemiologic studies included in this review. [@R12] summarized each of the major epidemiologic studies of CPF exposure and birth outcomes in children, based on authors' reported findings, and provided comprehensive analyses of exposures. This review differs from the [@R45] review of CPF and birth weight, the [@R38] review of pesticides and birth outcomes, and the [@R12] reviews by (1) providing comparisons of methodologies (including exposure measurement) and results; (2) reporting in tables the magnitude and direction of associations and 95% confidence intervals so that the reader can evaluate the precision of estimates and whether the direction of associations are consistent for similar exposure-outcome associations across studies; (3) considering the potential role of systematic error (bias); (4) discussing findings from the human studies in a causal framework (e.g., data addressing strength of the association, consistency across studies, exposure-response patterns of association); and (5) directly comparing the human data with the relevant animal data for biological plausibility.

In summary, this article evaluates whether the epidemiologic data indicate a strong or otherwise meaningful pattern of association of CPF exposure with birth weight, birth length, and head circumference at birth across different cohort studies. This is one of the scientific issues considered to be of primary importance in evaluating children\'s health assessment for CPF, including determination of uncertainty factors required under FQPA.

METHODS {#s2}
=======

Scope of the Review {#s3}
-------------------

The scope of the literature search included epidemiologic studies that investigated postulated associations between in utero exposure to CPF and growth endpoints in neonates, including head circumference, birth weight and length, and longitudinal growth indices in children; however, no studies met our inclusion criteria that included longitudinal growth indices in children. Abdominal circumference and ponderal index (PI; analogous to the body mass index in adults) were evaluated in some studies and results are included. Studies that reported results for adolescents or adults were excluded. The literature search was not limited by the geographic location of the study; however, our review includes only peer-reviewed studies that were published in English. Case reports and case series were excluded because they do not test hypotheses, estimate effects, or otherwise provide information on associations between an exposure and an outcome. Studies based on accidental or intentional poisonings were also excluded because this review is focused on evaluating effects of exposures resulting from standard uses (e.g., agricultural and residential).

All studies that inferred CPF exposure but did not directly measure and quantify exposure levels were excluded. This included any study that evaluated CPF exposure based on the residential location of the study participant with respect to agricultural activities (e.g., distance to nearest farm). Studies that measured air CPF concentrations at the individual level were included. Studies that described CPF biomonitoring but did not evaluate an association between exposure and the growth indices of interest were evaluated, but were not included in our final review. Because AChE inhibition is considered to be a mode of action for CPF, results on AChE levels and these outcomes from one of the studies are also reported.

Outcomes of interest were based strictly on the epidemiologic studies. To address the question of biological plausibility, animal data from robust study designs for endpoints related to those measured in the epidemiologic studies were evaluated. The inclusion criteria for in vivo animal studies were at least 3 CPF dose levels and 20 litters/dose level, the minimum regulatory requirements for reproduction and developmental studies to enhance confidence in the data. In addition, the route of exposure had to be relevant to human exposures, and the period of exposure had to include gestational exposures. Because there were no longitudinal epidemiologic studies measuring height and weight at different ages in children, the literature search for animal studies was restricted to outcomes of fetal weight or birth weight. Other relevant findings reported in these selected animal studies (e.g., AChE inhibition, maternal toxicity, and general developmental toxicity data) that aid in evaluation of birth or fetal weight were also evaluated.

Literature Search {#s4}
-----------------

The literature search included articles published in English through May 31, 2011. For the epidemiologic studies, a comprehensive search of the published literature was conducted in MEDLINE using the following search terms: "organophosphate," OR "organophosphorus," OR "chlorpyrifos," "head circumference," "head size," "birth weight," "birth length," "weight," "length," "fetal growth," OR "infant growth," "Ponderal Index," "small for gestational age," "small-for-gestational-age," "small size," "birth outcome." In addition, reference lists in recent reviews on CPF were crosschecked to identify any relevant papers that may have been missed by our search terms.

For the animal studies, MEDLINE was used to search for published journal animal articles written in English using the following search terms: chlorpyrifos and (development or reproduction or developmental) and ("birth weight" or "body weight" or "fetal weight" or "weight") and (rat or rats or mice or mouse or rodent or mammal or monkey or primate or animal) NOT ("bugs" or "cockroach" or "in vitro" or "zebrafish" or "cows" or "cow"). The following inclusion criteria were intended to ensure robustness and reliability of the animal studies and relevance to the human studies on birth outcomes: gestational exposures, 3 CPF dose levels, 20 or more litters per dose group, the litter was the experimental unit of analyses for fetal or pup birth weight, route of exposure was relevant to humans (oral, dermal, or inhalation), and data were presented. Of the 43 papers found, only 11 were original papers involving gestational exposures. Of these 11 papers, 5 were eliminated because the sample size was 5--10, the litter was not the experimental unit, and/or the route of exposure was subcutaneous (sc) injections. Although the sc injection route might have advantages for investigative mechanistic studies, it can affect the pharmacokinetics of CPF, such as bypassing first-pass metabolism (Marty et al. 2007; Slotkin et al. 2006), and degree of cholinesterase (ChE) inhibition and toxicity (Carr and Nail 2008). An exception was made for one oral study with a sample size of 10 that was included because the primary focus of this study was to evaluate the effect of CPF on body weight ([@R17]).

CPF and OP Biomarkers Included in This Review {#s5}
---------------------------------------------

This review focused on studies that analyzed the associations between biomarkers of CPF and birth outcomes. The CPF and other OP biomarkers ([Table 1](#T1){ref-type="table"}) included in this review and their specificity to CPF exposure are as follows ([@R4]; [@R6]; [@R25]): •CPF and chlorpyrifos-oxon (CPO) are biomarkers of highest specificity for CPF that are measured in blood plasma or serum. CPF is bioactivated to CPO, the primary toxic active metabolite of concern. Environmental exposure to CPO is also possible ([@R4]).•3,5,6-Trichloro-2-pyridinol (TCPy) is the most common urinary biomarker of CPF exposure, but with important limitations including that it may reflect exposures other than the parent compound CPF. Briefly, CPO is rapidly hydrolyzed to TCPy and diethylphosphate (DEP) ([Figure 1](#F1){ref-type="fig"}). CPF can also be dearylated to form TCPy and diethylthiophosphate (DETP) ([Figure 1](#F1){ref-type="fig"}). However, TCPy is also a metabolite of chlorpyrifos-methyl and triclopyr ([@R4]; [@R40]). It is an environmental degradate present in food, the environment, or homes, as a breakdown product from exposure to CPF, CPO, or chlorpyrifos-methyl ([@R4]; [@R12]; [@R40]). Significant intra-individual variability in repeat urine samples from the same individual has been observed ([@R40]).•Diethylphosphates (DEPs) represent a broad class of OP metabolites measured in urine that include DEP DETP and diethyldithiophosphate (DEDTP). Only DEP and DETP are metabolites of CPF ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). DEPs are relatively nonspecific as a biomarker of CPF because other OP are metabolized to DEPs and may be present in the environment ([Table 1](#T1){ref-type="table"}).•Dimethyl phosphates (DMPs) are urinary metabolites that cannot be formed from CPF ([Table 1](#T1){ref-type="table"}). They are metabolites of several methyl OF, including malathion and chlorpyrifos methyl (a pesticide registered separately from CPF). These metabolites are important to consider in evaluation of whether associations between DAPs and birth outcomes are more relevant to DMPs compared to DEPs.•Dialkyl phosphates (DAPs) are a class of OP metabolites measured in urine, which include both DEPs and DMPs ([Table 1](#T1){ref-type="table"}). Therefore, DAPs are highly questionable biomarkers of CPF compared to DEPs because they include metabolites that cannot be formed from CPF. As with DEPs, DAPs are also a nonspecific environmental degradate of OF!

![Major metabolic pathways of chlorpyrifos metabolism. CPF is metabolized by cytochrome P-450 (CYP). CPO is the primary toxic metabolite and is detoxified by esterases including carboxylases and paraoxonase (PON1) (color figure available online).](uteb15_281_f1){#F1}

###### 

Biomarkers of Organophosphate Exposures and Their Relevance to Chlorpyrifos

  Chemical name
  ---------------

Urinary biomarkers that cannot be formed from CPF.

"DEPs" refers to broad class of urinary OP metabolites containing ethyl groups.

"DMPs" refers to broad class of urinary OP metabolites containing methyl groups that are not biomarkers of CPF.

"DAPs" refers to DEPs and DMPs collectively and include OP metabolites that are not biomarkers of CPF.

EPIDEMIOLOGIC STUDY RESULTS {#s6}
===========================

Epidemiologic Studies Included in This Review {#s7}
---------------------------------------------

[Table 2](#T2){ref-type="table"} summarizes the study characteristics (including consideration of smoking, alcohol, and drug exposure) of the eight epidemiologic reports evaluating the association between CPF exposure and growth outcomes in neonates. These were reports from the following four cohorts: the Columbia Center for Children\'s Environmental Health (CCCEH) ([@R26]; [@R29]; [@R42]; [@R39]), the Mount Sinai Center for Children\'s Environmental Health and Disease Prevention Research (Mt. Sinai) ([@R5]; [@R43]), the Center for Health Assessment of Mothers and Children of Salinas (CHAMACOS) ([@R13]), and the New Jersey Cohort of Pregnant Women and their Children (New Jersey) ([@R3]).

###### 

Characteristics of the Epidemiologic Studies Reporting Associations Between Chlorpyrifos or Relevant Metabolites and Fetal Growth Outcomes

  Study Cohort and Location                                                                               Author (sample size; enrollment or birth dates)                                                            Consideration of tobacco, ethanol, drug exposure                                                                                                                                                                                                                                                                             Chlorpyrifos measure or metabol ite[^a^](#T2-FN1){ref-type="table-fn"}                                                           Detection limit/mean or median exposure levels                                                                                                                                           Source and timing of sample                                                                       Head circumference   Birth weight   Birth length   Ponderal index   Abdominal circumference
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------- -------------- -------------- ---------------- -------------------------
  Columbia Center for Children\'s Environmental Health (New York, USA)                                    Perera et al. 2003 (n = 263; n = 113 for plasma) Enrolled 9/98--11/99[^b^](#T2-FN2){ref-type="table-fn"}   Illicit drug users and active smokers were excluded based on self-reported history and plasma cotinine concentrations \> 15 ng/ml. Covariates included maternal self-reported environmental tobacco smoke in the home. Cotinine and alcohol consumption were not significant predictors of outcomes and were not included.   CPF (parent compound)                                                                                                            Detected in 94% of samples, arithmetic mean = 7.6 pg/g                                                                                                                                   Umbilical Cord Plasma[^c^](#T2-FN3){ref-type="table-fn"}                                          X                    X              X                               
  Whyatt et al. 2004 (n = 314; n = 286[^f^](#T2-FN6){ref-type="table-fn"} cord blood) Births 3/98--7/02   CPF (parent compound)                                                                                      31% of CPF samples were below LOD (LOD not reported)Mean = 4 pg/g (umbilical cord plasma)                                                                                                                                                                                                                                    Umbilical Cord Plasma[^c^](#T2-FN3){ref-type="table-fn"} Personal air samples were collected in the 3rd trimester for two days   X                                                                                                                                                                                        X                                                                                                 X                                                                   
  Whyatt et al. 2005 (n = 571; n = 341 cord blood) Enrolled 1/98--1/04                                    CPF[^d^](#T2-FN4){ref-type="table-fn"} (parent compound)                                                   Detected in 64% of cord blood samples, mean = 3.7 pg/g; detected in 99.7% of air samples;mean = 14.3 ng/m^3^                                                                                                                                                                                                                 Umbilical Cord Plasma[^c^](#T2-FN4){ref-type="table-fn"} Personal air samples were collected in the 3rd trimester for two days   X                                                                                                                                                                                        X                                                                                                 X                                                                   
  Rauh et al. 2006 (n = 254) Births 2/98--5/02                                                            CPF (parent compound)                                                                                      LOD = 0.5--1 pg/g; 80 samples below LOD Median levels not provided                                                                                                                                                                                                                                                           Umbilical Cord Plasma[^c^](#T2-FN3){ref-type="table-fn"}                                                                         X                                                                                                                                                                                        X                                                                                                 X                                                                   
  Mt. Sinai Center for Children\'s Environmental Health and Disease Prevention Research (New York, USA)   Berkowitz et al. 2004 (n = 404) Enrolled 3/98--3/02                                                        Women consuming more than 2 alcoholic beverages per day or using illegal drugs were excluded. "Active and passive cigarette smoking were not included in the final models because they did not affect the results and only increased the variance. ([@R5])."                                                                 TCPy                                                                                                                             LOD level = 11.0 μg/L; 57% of samples were below LOD                                                                                                                                     Maternal urine collected in 3rd trimester[^e^](#T2-FN5){ref-type="table-fn"}                      X                    X              X                               
  Wolff et al. 2007 (n = 404) Enrolled 3/98--3/02                                                         DER, DAP                                                                                                   DEP detected in 88.1%, DAP detected in 97.2%; Median = 18.1 nm/L DEP, 75.9 nm/L DAP                                                                                                                                                                                                                                          Maternal urine collected during the 3rd trimester                                                                                X                                                                                                                                                                                        X                                                                                                 X                    X                                              
  The Center for Health Assessment of Mothers and Children of Salinas (California, USA)                   Eskenazi et al. 2004 (n = 488) 10/99--10/00                                                                "Smoking, alcohol, and illicit drug use were not included in the models because very few women reported use and controlling for these variables did not alter the results." Environmental tobacco smoke and caffeinated beverages also did not alter the results and were not included.                                      TCPy, DEP, DAP                                                                                                                   TCPy detected in 77% of samples; median 3.3 μg/L DEP and DAP detected in 99.8% of samples;median = 22 nmol/L for DEP, 1 36 nmol/L for DAP                                                Maternal urine collected at mean = 13 wks (range 4--29 wks) and mean = 26 wks (range 18--39 wk)   X                    X              X              X                
  New Jersey Cohort (New Jersey, USA)                                                                     Barr et al. 2010 (n = 150) 7/03--5/04                                                                      "The vast majority of the population was non-smoking (96%)." Women were excluded if they were taking medications that could interfere with metabolism of environmental chemicals. No information on controlling for smoking, alcohol or illicit drug use.                                                                    CPF (parent compound)                                                                                                            Maternal Blood: Mean = 0.09ng/g (SD = 0.87), Median = 0.0007 ng/g; detected in 98.6% of samples Cord Blood: Mean = 0.55ng/g (SD = 0.73), Median = 0.0007; detected in 62.8% of samples   Maternal blood (collected immediately prior to birth) and umbilical serum                         X                    X              X                               X

LOD = limit of detection; SD = Standard deviation; See footnotes in Table 2 for additional covariates included in the final statistical models.

CPF = chlorpyrifos; DAP = total dialkyl phosphates; DEP = diethylphosphate; TCPy = 3,5,6-trichloro-2-pyridionol.

Based on Whyatt et al. 2002 as cited by [@R26].

Maternal blood was used when cord blood was unavailable.

Chlorpyrifos was also measured in maternal air samples during the third trimester of pregnancy.

Maternal blood and cord blood was also used to assess PON1 activity at the *PON1* polymorphisms.

Based on 256 cord blood samples plus 31 imputed values based on maternal cord levels.

All four cohort studies presented results for head circumference, birth length, and birth weight. Two studies, the Mt. Sinai study ([@R43]) and CHAMACOS study ([@R13]), reported results for the ponderal index, calculated as (birth weight in g × 100)/(length in cm)^3^ ([@R13]). Results for abdominal circumference were reported only by the New Jersey cohort study ([@R3]). Although all four publications cited from the CCCEH cohort reported results that met our inclusion criteria, the purpose of the publication by [@R29] was to evaluate associations between prenatal CPF exposures and neurobehavioral outcomes. We review those results in a separate article ([@R18]).

The CCCEH cohort included nonsmoking women, ages 18--35 yr, self-identified as African American or Dominican residing in northern Manhattan or the South Bronx for at least 1 yr before pregnancy ([@R26]; [@R42]; [@R39]). The women were included if they were free of diabetes, hypertension, or known HIV (human immunodeficiency virus). Covariates included in the final models were race/ethnicity, gestational age, parity, maternal prepregnancy weight and new weight gain during pregnancy, maternal self-reported environmental tobacco smoke in the home, sex of the newborn, and season of delivery. Annual household income, maternal education, maternal marital status, material hardship during pregnancy, and degree of housing disrepair were not included in the final model because they did not affect the results ([@R42])

The Mt. Sinai cohort included women pregnant for the first time with one child without serious chronic diseases such as diabetes, hypertension, thyroid disease, or serious pregnancy complication that could affect fetal growth and development. The mother and infant were excluded if there was severe prematurity or congenital malformation. The largest ethnic group was Hispanics, followed by African-Americans and whites. Models included race/ethnicity, infant sex, and gestational age. Prepregnancy body mass index, maternal weight gain, blood lead levels, and cesarean section delivery were not included in the final models because they did not affect the results. Marital status and educational levels were not included in the analysis because they were "too closely correlated with race/ethnicity" ([@R5]).

The CHAMACOS cohort consisted primarily of low-income Latina women living in an agricultural community in the Salinas Valley, California, without gestational or preexisting diabetes, hypertension, twin births, or stillbirths ([@R13]). Women with infants diagnosed with congenital anomalies at birth were included. Approximately 42% of the women worked in the field during pregnancy or worked at other agricultural jobs (e.g., packing shed, nursery and greenhouse work), and 85% had agricultural workers living in their homes during pregnancy. All models were adjusted for gestational age, and included variables for maternal age, pregnancy weight gain, week of initiating prenatal care, parity, infant sex, mother\'s country of birth, body mass index, and family income.

The New Jersey cohort included women pregnant with one nonanomalous fetus scheduled for an elective cesarean birth at term at Saint Peter\'s University Hospital in New Bruswick, NJ. Women were excluded if the hemoglobin level was less than 8 mg/dl, if there was evidence for labor or rupture of membranes at the time of operative delivery, and if they were taking medications that might interfere with metabolism of environmental chemicals. The statistical models were adjusted for maternal age, primagravida, maternal prepregnancy body mass index, infant sex, and gestational age.

Biomarkers of CPF Exposures {#s8}
---------------------------

The main CPF exposures reported in the reviewed studies were measured and quantified from biological specimens obtained directly from women during pregnancy or from the umbilical cord at delivery ([Table 2](#T2){ref-type="table"}). This included measuring the parent compound CPF in maternal or umbilical cord blood, as well as measuring metabolites of CPF in maternal urine during pregnancy, including TCPy, DEPs, and DAPs. As discussed in greater detail in the methods section, TCPy is a more specific biomarker of CPF than the nonspecific OP urinary metabolites DEPs and DAPs. All of these urinary metabolites have limitations as biomarkers for CPF because they may also reflect exposure to environmental degradates of OP (including CPF) or to other OP ([@R25]).

The New Jersey cohort ([@R3]) analyzed birth outcomes based on maternal (immediately prior to birth by Cesarean section) and umbilical cord serum levels of CPF. Maternal and cord serum samples were not correlated in the New Jersey cohort (r = 0.12), and results for these two measures were reported separately ([@R3]). In contrast, the CCCEH cohort study ([@R26]; [@R29]; [@R42]; [@R39]) analyses were based on umbilical cord plasma levels of CPF at birth and air measurements collected during the third trimester of pregnancy. In the CCCEH cohort, maternal plasma levels were used only in cases where cord samples were not collected because maternal and cord plasma samples were correlated (*r* = .76), and estimates of cord plasma levels from maternal plasma were based on formulas derived from a regression analysis ([@R42]). The CPF levels in maternal air samples were collected via a personal air monitor that was worn in a backpack during the daytime for two consecutive days and placed by the bed while sleeping during the third trimester of pregnancy ([@R39]).

The urinary metabolites TCPy, DEPs, and DAPs were measured in the Mt. Sinai and CHAMACOS studies ([@R5]; [@R13]; [@R43]). The CHAMACOS and Mt Sinai studies measured the following six DAPs ([@R13]; [@R43]): DEP DETP, DEDTP DMP DMDTP and DMTP The first three were summed to obtain the total concentration of DEPs, and the latter three were summed to obtain the total concentration of DMPs. DAPs were defined as the sum of all the DEPs and DMPs. DMPs are discussed in this review only when relevant to interpreting associations reported for DAPs.

Exposure to OP pesticides was also assessed in the CHAMACOS study by measuring AChE in whole blood and BuChE in plasma from mothers during pregnancy and from the umbilical cord at delivery ([@R13]; [@R43]). [@R43] also measured BuChE in maternal plasma during the third trimester of pregnancy in the Mt. Sinai study. AChE and BuChE are nonspecific measures of general exposure to OP and possibly carbamates. Neither cohort study measured CPF in maternal plasma.

Maternal Information and Self-Reported CPF Exposure {#s9}
---------------------------------------------------

Each cohort study administered a questionnaire to obtain information on study participants; however, the specific contents of the survey varied across the cohorts. The New Jersey cohort ([@R3]) also obtained information about maternal characteristics from hospital records. In general, the objectives of the surveys were to obtain information about demographic characteristics, personal habits, maternal medical history, and the personal use of pesticides among the study participants. As described earlier and in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, information obtained from the questionnaires may or may not have been used in the final multivariate models presented in each study. The CHAMACOS study ([@R13]) administered the questionnaire two times during the pregnancy (first interview: mean = 13 wk, range = 4--29 wk; second interview: mean = 26 wk, range = 18--39 wk). The women who participated in the CCCEH study ([@R26]; [@R29]; [@R42]; [@R39]) and the Mt. Sinai study ([@R5]; [@R43]) completed their surveys during the third trimester of pregnancy. The timing of questionnaire administration was not stated for the New Jersey cohort ([@R3]). Women in that study were recruited from lists of patients scheduled for elective cesarean birth, so it seems plausible that questionnaires were administered during the third trimester of pregnancy. Although pesticide exposure data were collected via questionnaire, none of the studies reported associations between selfreported CPF exposure and any of the birth outcomes.

###### 

Summary of growth indices by metabolite

  --
  --

Associations of CPF and Metabolites With Growth Outcomes {#s10}
--------------------------------------------------------

[Table 3](#T3){ref-type="table"} provides the results of analyses of growth indices by CPF or metabolite for each of the reports included in this review. [Table 4](#T4){ref-type="table"} summarizes results relevant to the potential interaction of PON1 enzyme activity (phenylacetate as a substrate) or PON192 genotype and CPF-related biomarkers of exposure for each of the growth indices.

###### 

Summary of PON1 results presented by the Mt. Sinai Cohort that are related to potential CPF biomarker exposure

  --
  --

Head Circumference {#s11}
------------------

No statistically significant associations were observed between head circumference and CPF in blood (maternal serum or umbilical cord plasma or serum) or with TCPy measured in the urine in the CCCEH ([@R26]; [@R29]; [@R42]; [@R39]), New Jersey ([@R3]), Mt. Sinai ([@R5]), or CHAMACOS ([@R13]) cohorts. There was no statistically significant association between maternal personal air samples of CPF during the third trimester of pregnancy and head circumference in the CCCEH cohort ([@R42]).

Associations between head circumference and the less specific biomarkers DEP and DAP were in opposite directions in the two studies that evaluated these associations. Specifically, the CHAMACOS cohort reported a statistically significant 0.32-cm increase in head circumference associated with each 1-unit (nmol/L, log~10~ scale) increase of the DAP metabolite (no creatinine adjustment) ([@R13]). In contrast, the Mt. Sinai cohort study reported a statistically significant 0.26 cm decrease in head circumference for every 1-unit (nmol/L, log~10~ scale) increase of the DAP metabolite (no creatinine adjustment) ([@R43]). [@R43] also reported a numerical 0.25 cm decrease in head circumference associated with the DAP metabolite when the model was adjusted for creatinine. A similar discordant pattern was reported across the CHAMACOS and Mt. Sinai cohorts for the DEP metabolite; however, these associations were statistically nonsignificant ([Table 3](#T3){ref-type="table"}).

Birth Weight {#s12}
------------

The CCCEH cohort study reported no statistically significant associations between personal air levels of CPF collected over a period of 48 h during the third trimester of pregnancy and birth weight. However, there were statistically significant inverse associations between umbilical cord plasma CPF and birth weight in four separate publications of data from the CCCEH cohort. Specifically, [@R26] reported a statistically significant 0.04-g decrease in the log of birth weight among all participants in the cohort for every unit increase (log-transformed pg/g) in CPF. Statistically significant results of a similar magnitude were observed for African American participants but not Dominican participants. Subsequent analyses did not stratify results on ethnicity, because the tests for interaction were statistically nonsignificant. Information beyond the lack of significance of the statistical tests of interaction was not provided in the other CCCEH reports. Thus, in the absence of stratified data, it is unknown whether patterns of association were materially similar or different for the two ethnic groups, regardless of the results of the statistical tests for other CCCEH publications.

[@R42] reported a statistically significant 42.6-g decrease for each unit increase (log transformed pg/g) of CPF. Additional analyses indicated that this association was not strictly monotonic, and was driven by stronger associations at higher levels of exposure. Specifically, when stratified into 4 exposure groups (CPF levels \< LOD \[level of detection\], CPF levels \> LOD divided into tertiles), the birth weight in the highest exposure tertile averaged 150 g lower (95% CI: −28.7 to −12.5) than the undetectable group, whereas the birth weight in the lowest exposure tertile was 39.2 g higher on average (95% CI: −107.3 to 185.7g) ([Table 3](#T3){ref-type="table"}). [@R29] reported that participants with CPF levels \> 6.17 pg/g had a statistically significant lower mean birth weight than participants with CPF \< 6.17 pg/g (3239.58 g versus 3450.93 g, respectively). This cutoff point (6.17 pg/g) was based on combining the undetectable group with the two lower tertiles into a new "low-exposure" group and comparing to the upper tertile.

In 2000--2001, the U.S. EPA implemented regulatory actions to phase out the residential use of CPF. [@R39] reported that children in the CCCEH cohort born prior to January 1, 2001, had a statistically significant 67.3-g decrease in birth weight per unit increase in CPF (log transformed pg/g; *n* = 237). In contrast, the association was positive and statistically nonsignificant among children born after that date (*n* = 77). A similar analysis using third-trimester personal ambient air samples of CPF was statistically nonsignificant for children born both before and after January 1, 2001 ([@R42]).

There were no statistically significant associations between CPF in maternal serum and umbilical cord serum and birth weight in the New Jersey cohort study, which enrolled participants beginning in July, 2003, after cancelation of residential uses ([@R3]) ([Table 3](#T3){ref-type="table"}). None of the reported associations between TCPy ([@R5]; [@R13]), DEP or DAP ([@R13]; [@R43]), and birth weight in the Mt. Sinai and CHAMACOS studies was statistically significant, and the associations varied in magnitude, with both negative (inverse) and positive findings. Residential exposures to OP pesticides, including CPF, in the Mt. Sinai study have been considered to be relatively similar to the CCCEH study in terms of pathway, amount, rate, and type ([@R25]), and TCPy is a relatively specific biomarker of CPF compared to other urinary metabolites. As described previously, however, TCPy levels may reflect exposures other than, or in addition to, CPF (parent compound) ([@R4]; [@R25]). Nevertheless, the inverse associations between umbilical cord CPF levels and birth weight reported by the CCCEH cohort study were not corroborated by a similar cohort in New York with residential exposures and data on TCPy and DEP; nor did the CCCEH investigators observed similar findings based on air monitoring data.

Birth Length {#s13}
------------

The CCCEH ([@R26]; [@R29]; [@R42]; [@R39]) and New Jersey cohorts ([@R3]) evaluated the association between CPF in serum and birth length. There were no statistically significant associations between CPF in maternal serum and umbilical cord serum and birth length in the New Jersey cohort ([@R3]). The CCCEH cohort studies reported mixed results, depending on the analysis. Specifically, [@R26] reported a statistically significant 0.02-cm decrease in birth length among all participants for every unit increase (log transformed pg/g) in cord plasma CPF. Statistically significant results of similar magnitude were observed among the Dominican participants but not the African American participants. This was in contrast to the pattern observed by [@R26] for birth weight, a pattern that appeared to be limited to African American infants. As discussed previously for birth weight, subsequent analyses that reported data on birth length did not stratify on ethnicity, because the statistical tests for interaction were nonsignificant ([@R29]; [@R42]; [@R39]). [@R39] observed that children born prior to January 1, 2001, had a significant 0.43-cm decrease in birth length for every unit (log transformed pg/g) increase in cord plasma CPF, but there was essentially no association among newborns after this date.

When stratified into 4 exposure groups (CPF umbilical cord levels \< LOD, CPF levels \> LOD divided into tertiles), the birth length in the highest exposure group averaged 0. 75 cm less than in the group with CPF levels below the LOD; however, this association was statistically nonsignificant and the overall pattern did not appear monotonic ([@R42]) ([Table 3](#T3){ref-type="table"}). [@R29] reported similar mean birth lengths (50.02 cm versus 51.05 cm, respectively) among participants with CPF \> 6.17 pg/g versus those with CPF \< 6.17 pg/g. Despite the statistically significant inverse association reported in the linear regression analyses ([@R26]; [@R42]; [@R39]), analyses that compared each exposure tertile to the nondetect group yielded statistically nonsignificant results ([@R42]), and the mean birth length was similar for the highest exposure tertile compared to the other groups combined ([@R29]). Furthermore, there were no material or statistically significant associations between personal air levels of CPF and birth length in the CCCEH cohort.

None of the reported associations between TCPy ([@R5]; [@R13]), DEP or DAP ([@R13]; [@R43]), and birth length was statistically significant. The direction of the associations for the DEP and DAP metabolites was generally positive in the CHAMACOS cohort ([@R13]) but mostly negative in the Mt. Sinai cohort ([@R43]). Taken together, the evidence for an association between CPF and birth length is weak.

Ponderal Index and Abdominal Circumference {#s14}
------------------------------------------

The associations between TCPy and/or DEP and DAP and ponderal index were evaluated in the CHAMACOS ([@R13]) and Mt. Sinai cohorts ([@R43]), with generally null findings. The association between CPF and abdominal circumference of the neonate was evaluated by the New Jersey cohort ([@R3]). Mean abdominal circumference was approximately the same for participants categorized above or below the 75th percentile for CPF levels in maternal and umbilical cord sera ([@R3]).

Potential Effect Modification by PON1 Status {#s15}
--------------------------------------------

Analyses based on PON1 polymorphisms and enzyme activity were included only in reports from the Mt. Sinai cohort study ([@R5]; [@R43]). Briefly, CPF is metabolized to the toxic metabolite CPO, which is then rapidly hydrolyzed to TCPy by microsomal esterases including PON1 and CPF oxonase, or by nonenzymatic hydrolysis ([@R25]). The authors were interested in evaluating if any effects of exposure to OP may be modified by PON1 enzyme activity level or genotype.

[Table 4](#T4){ref-type="table"} summarizes results relevant to the potential interaction of PON1 enzyme or PON1 genotype and CPF-related biomarkers of exposure that were presented in two reports from the Mt. Sinai Study ([@R5]; [@R43]). [@R5] stratified maternal PON1 enzyme activity into "low," "medium," and "high" based on the tertile distribution. The range of PON1 enzyme activity in the different PON1 tertiles was not described, but the cut points for PON1 enzyme activity (as measured in plasma using phenylacetate as a substrate) are assumed to be \<96, 97--116.6, and 116.7--200 mg/m-ml for PON1 tertiles 1, 2 and 3, respectively, as reported for the same cohort by Wolf et al. (2007).

[@R5] analyzed associations among TCPy; PON1 activity for each of five PON1 genotypes; and birth weight, birth length, or head circumference. The five different PON1 genotypes (Q192R, L55M, - 909, −162, and −108) were measured in maternal blood samples obtained during the third trimester and cord blood samples were obtained at birth. [@R43] evaluated associations among DEPs, DMPs, or DAPs; maternal blood (third trimester) PON1 activity or PONQ192R genotype; and birth weight, birth length, or head circumference. [@R5] considered mothers with genotype PON192 RR and PON192 QQ to possess the phenotype of higher and lower PON1 activity, respectively, based on previous research.

There were no statistically significant interactions between PON1 activity and TCPy levels for any of the birth outcomes ([@R5]). There was a statistically significant positive trend in head circumference across PON1 tertiles among those with TCPy levels above the limit of detection (LOD), but not below the LOD ([Table 4](#T4){ref-type="table"}). However, the magnitude of the head circumference for these infants was similar across PON1 activity tertiles for the TCPy \< LOD groups (33.6, 33.7, and 34.1 cm) and TCPy \> LOD group (33.3, 34, and 34.1 cm) (see [Table 4](#T4){ref-type="table"}). Given the absence of a main effect for TCPy, and the similarity of patterns among those with TCPy levels above and below the LOD, it is not surprising that the test for interaction between PON1 activity and TCPy levels for head circumference was statistically nonsignificant. Furthermore, a significant trend was observed in head circumference when PON1 activity was considered alone, without level of TCPy, with adjusted means of 33.5, 33.9, and 34.1 cm for tertiles 1, 2, and 3, respectively. Thus, there is uncertainty about the contribution CPF exposure has on observed PON1 associations in the Mt. Sinai Study. At present, evidence that CPF may exert a detrimental effect on head circumference in infants of mothers who exhibit low PON1 activity is weak.

[@R43] reported "weak, nonsignificant inverse associations" with three birth outcomes (independent of PON1 status): DEPs with birth weight, DEPs with ponderal index, and DAPs with head circumference ([@R43]). Based on these results, interactions between levels of DEPs or DAPs and PON1 status were evaluated. In addition, birth length was shorter by 0.68 cm among mothers with PON192RR (slower) than PON192QQ (faster) genotype independent of biomarker exposure ([@R43]).

There was no statistically significant interaction among DEP level, PON1 activity level, and birth weight; however, there was a statistically significant 164 g (5%) decrease in birth weight of babies born to mothers with slow PON1 enzyme activity and DEP levels above the median compared to babies born to mothers with fast PON1 enzyme activity and DEP levels below the median ([Table 4](#T4){ref-type="table"}). A similar pattern was observed in the PONQ192R/DEP interaction analyses, in which babies born to women with the PON192RR genotype (slow) and DEP levels above the median weighed 199 g less (6% decrease) than babies born to women with the PON192QQ genotype (fast) and DEP levels below the median, but the test for interaction was not significant. In addition, the birth weight of babies born to women with the PON192QQ genotype who had DEP levels below the median was higher than for babies born to women with the PON192QQ (fast) genotype who had DEP levels above the median, but similar comparisons across heterozygotes and those with PON192RR (slow) genotypes were statistically nonsignificant. There was no statistically significant effect modification of PON1 activity by TCPy on birth weight for the same cohort ([@R5]); thus, the interpretation of the DEP-PON1 activity or genotype findings with respect to CPF is not clear. Only results of analyses of DEPs, PON1 status, and birth weight were reported by [@R43]. [@R43] stated that after taking into account the interaction of DAPs with PON1, a "small effect" of DAPs on head circumference ([Table 3](#T3){ref-type="table"}) was no longer present and there were no statistically significant associations with Ponderal Index.

Acetylcholinesterase (AChE) and Fetal Growth {#s16}
--------------------------------------------

The CHAMACOS study ([@R13]) measured AChE levels in maternal blood collected at the second pregnancy interview, in umbilical cord blood, and in predelivery maternal blood. None of these measures was statistically significantly associated with the three fetal growth measures of interest, specifically head circumference, birth weight, or birth length. There was no significant correlation between DAP levels and ChE levels collected at the second pregnancy interview (Pearson *r* = .02). Furthermore, somewhat surprisingly, there was a weakly positive but statistically significant correlation between DAPs measured in pregnancy urine and predelivery maternal blood (Pearson *r* = .11) and umbilical cord blood AChE levels (Pearson *r* = .13). [@R13] suggested that this deviation from the expected negative correlation may be a result of "substantial measurement error" in both variables, and/or because DAP metabolites are specific to OP, whereas AChE activity may also reflect exposure to *n*-methyl carbamate ([@R13]). The Mt. Sinai study measured BuChE in maternal blood and observed no association between DEP or DAP exposures or birth outcomes with maternal BuChE in the Mt. Sinai Study ([@R43]).

DISCUSSION OF EPIDEMIOLOGIC STUDIES {#s17}
===================================

Our review of the data from four epidemiologic cohort studies identified a number of statistically significant results, several resulting from different analyses of the same exposure-outcome association in the same cohort study using different exposure modeling approaches or study population subgroups (e.g., CPF measured in cord plasma and birth weight in the CCCEH study, [Table 3](#T3){ref-type="table"}). There were no notable or consistent patterns of association across the different cohort studies. One possible reason for the lack of consistency across the studies is, of course, that there is no "true" causal association between exposure to CPF and any of the fetal growth outcomes evaluated in these studies. Alternative explanations for these data should also be considered. For example, no more than two of the four cohort studies evaluated associations between the same biomarker of exposure and the same outcome. Thus, one needs to consider the studies in terms of the level of information they provide about CPF specifically (as opposed to information about OP generally), as well as what is meant by "consistent findings" in the context of these four studies.

Two of the cohort studies (CCCEH and New Jersey) measured CPF in umbilical cord blood (plasma or serum). A strength of this approach is the use of a biomarker that is specific to CPF ([@R3]; [@R26]; [@R29]; [@R42]; [@R39]). Furthermore, the biomarker represents all sources of exposure (e.g., inhalation, ingestion, dermal). A limitation of this approach is that exposure and outcome information were measured at roughly the same point in time, making it difficult to establish a temporal relationship between exposures during gestation and outcome. The half-life of CPF in blood is relatively short, about 24 h ([@R3]). If exposure is relatively constant over time, then cord blood levels at birth may represent exposure levels throughout pregnancy; however, there were no data available to validate this assumption. In the CCCEH study, personal air monitoring CPF levels measured during the third trimester of pregnancy were only weakly correlated with CPF levels in cord plasma (*r* = .19) or maternal plasma at delivery (*r* = .21) ([@R39]).

There were no significant associations between personal air CPF levels measured during the third trimester on any of the birth outcomes ([@R42]; [@R39]). These associations between personal air CPF levels and birth outcomes remained nonsignificant when analyses were stratified on year of delivery before versus after January 1, 2001 ([@R42]). Indoor (collected continuously from 32nd week of pregnancy until delivery) and maternal personal air levels (collected over 48 h during 32nd week of pregnancy) of CPF were correlated (*r* = .85) and both declined four- to fivefold between 2001 and 2004 after the ban on residential uses ([@R41]). Maternal personal air levels also correlated with indoor samples collected immediately (*r* = .86) and 8 wk after (r = .87) the maternal air sampling ([@R41]). This suggests that maternal personal air levels of CPF may be reflective of inhalation exposures over 2 mo during the 3rd trimester of pregnancy that result from indoor residential uses. A limitation is that personal air samples may not reflect all possible routes of exposure. The extent to which noninhalation routes of exposure contributed to residential exposures is uncertain ([@R40]). The Mt. Sinai and CHAMACOS cohort studies had the advantage of estimating exposure based on maternal urine samples collected during pregnancy; thus, exposure measurement clearly preceded measurement of fetal growth outcomes and may better represent a time period of critical growth and development. On the other hand, these cohorts used less specific biomarkers of CPF exposure, namely, TCPy, DEPs, and DAPs. As discussed previously, the metabolites in urine may reflect exposures other than, or in addition to, CPF. All of the studies suffered by relying on measurements collected at one (or at most, two) points in time. The extent to which the measures used in these analyses provided a valid estimate of exposure to CPF and/or other OP during the course of pregnancy is uncertain. For example, in a biomarker validation study (*n* = 102), conducted between 2001 and 2004, the CCCEH investigators ([@R40]) reported no marked association between CPF in cord plasma and the following other exposure measures: personal and indoor air CPF levels, maternal self-reported pesticide use, and TCPy levels in maternal samples during pregnancy or after delivery. A limitation of this validation study was the relatively low proportion of subjects with detectable CPF cord blood levels (19--29% of cord blood samples in 2001--2002, and none of the samples collected in 2003--2004) ([@R40]). A previous report from the CCCEH study indicated that even though CPF in maternal personal air samples also decreased from 2001 to 2004, CPF was still detectable in almost all of the air samples ([@R41]).

Another possible explanation for the lack of consistent findings is different levels of exposure to CPF across the studies. Briefly, CPF exposure levels in the two New York cohorts have been estimated to be higher than exposures in the CHAMACOS cohort ([@R12]; [@R13]). The main source of exposure in both of the New York cohorts was home pesticide use, whereas in the CHAMACOS study, the likely sources included diet and agricultural use. CHAMACOS participants reported working in the fields (28%) or at other jobs in agriculture, including packing shed, nursery, and greenhouse work (14%). Furthermore, [@R13] reported that few of the products found in the homes of CHAMACOS cohort study participants contained CPF.

The New Jersey cohort was assembled after home use of CPF had been phased out (July, 2003-May, 2004), and the time span of the CCCEH study includes both pre- and post-ban periods (1998--2002). The median cord sera CPF level reported for the New Jersey cohort was 0.0007 ng/g (0.7 pg/g) ([@R3]), which is lower than the mean cord plasma CPF level of 4 pg/g for the CCCEH cohort ([@R2]; [@R42]; [@R39]). [@R42]; [@R42]) presented data from the CCCEH stratified on date of birth before and after January 1, 2001, in an effort to evaluate the potential impact of the cancellation of residential use of CPF. Inverse associations between cord blood CPF and birth weight and birth length observed among births prior to 2001 were no longer present after January 1, 2001. [@R42] reported that cord plasma CPF levels in the CCCEH study were significantly lower among newborns after January 1, 2001 (geometric means of 0.6 pg/g after January 1, 2001, compared to 2.5 pg/g prior to January 1, 2001). [@R42] also commented that few newborns had high CPF exposure levels after 2001, but did not report the number exposed at different levels. Furthermore, [@R29] observed no statistically significant difference in mean birth length among newborns with cord blood CPF levels in the upper versus lower exposure categories ([Table 3](#T3){ref-type="table"}). Thus, further evaluation of the pattern of associations for birth length (and birth weight) at different exposure levels (i.e., dose response), including a comparison of these dose-response associations during the two time periods, may be helpful. One would expect the magnitude of associations at given exposure levels to be approximately the same regardless of the time period. Further analyses to evaluate other factors that potentially changed over time and may influence fetal growth may also be helpful, because these factors may also explain some of the changes observed. Finally, it should be noted that CPF biomarker levels in the CCCEH study were variable as reported by [@R29]. [@R29] reported the logarithmically transformed mean CPF level in cord blood for three time periods as follows: 0.92 pg/g (preban, before January 2000), 0.81 pg/g (midban, January 2000 to December 2000), and 0.90 pg/g (postban, January 2001 and later).

The potential role of uncontrolled or incompletely controlled confounding also needs to be considered as possible explanations for the weak to modest associations observed. The results from the New Jersey cohort study ([@R3]) were initially consistent with those of the CCCEH study for birth weight and birth length until they adjusted for covariates. The New Jersey study adjusted for fewer covariates overall compared to the CCCEH study, but there were some differences. Specifically, the New Jersey study adjusted for maternal age, whereas the CCCEH study did not. The New Jersey study adjusted for prepregnancy body mass index (BMI), whereas the CCCEH study adjusted for prepregnancy weight and net pregnancy weight gain. The differences in adjustment for these variables may or may not have changed the results.

Study design features resulted in few or no preterm births being included in the New York and New Jersey cohorts. [@R13] observed a lower rate of preterm births, a major cause of low birth weight, in the CHAMACOS cohort (6.4%) compared with Mexican-born women in the United States (10%). Relatively few women in any of the four cohort studies reported smoking during pregnancy. Specifically, approximately 6%, 5%, and 4% of the women in the CHAMACOS study, Mt. Sinai Study, and New Jersey study, respectively, reported smoking during pregnancy ([@R3]; [@R13]; [@R43]). Women were excluded from the CCCEH study if they reported any smoking during pregnancy or if cotinine levels in blood collected at delivery were above 15 ng/mL ([@R42]). Despite this restriction on maternal smoking, 38% of the women in the CCCEH study reported a smoker in the home ([@R42]), whereas only 8.3% of women in the CHAMACOS study reported living with a smoker during pregnancy ([@R14]). Only the CCCEH study reported results after adjustment for either environmental tobacco smoke or cotinine. Investigators from the CHAMACOS study indicated that results were similar after adjustment for either maternal smoking or environmental tobacco smoke, and that they did not include maternal smoking in the final model in part because of small numbers ([@R13]).

Regression modeling methods were used to evaluate the association between these metabolite levels and fetal growth outcomes, particularly head circumference, birth weight, and birth length. The regression models reported varied within and across the studies by several key factors, including the metabolite measured, the timing of exposure measurement (pregnancy or delivery), timing of data collection (before or after home use of CPF was banned), and the outcome. In addition, modeling choices such as using continuous versus categorical variables, performing logarithmic transformations on continuous variables, and inclusion of additional covariates varied across the studies. These differences need to be considered when evaluating the findings across studies. In addition, linear regression models were used for many analyses, but most studies did not describe models that tested this assumption of linearity or that formally evaluated nonlinearity. As one example, it would have been helpful if CCCEH investigators had offered guidance in interpreting the validity of the linear regression models in view of the results of the analyses of the categorical analyses, which indicated a possible nonlinear component to the association between CPF and birth weight ([@R42]).

Measures of fetal growth (birth weight, birth length, and head circumference) may be considered more objective than measures of cognitive or psychomotor development, but these endpoints are also subject to a number of sources of variability. These include genetic variables such as height and weight of the parents, nutrition, and uncertainties around dating of gestational age at birth (i.e., time from conception), as well as measurement error.

Considered together, the results from the four cohort studies have not indicated a consistent, strong association between biomarkers of CPF exposure and measures of fetal growth across the different cohort studies. A clear pattern of associations did not emerge when considering the relative specificity of the different biomarkers used in the studies, because essentially null results were observed for the New Jersey cohort study, which used CPF in cord serum as a biomarker, or for the CHAMACOS study, which used the biomarker TCPy (in addition to the less specific biomarkers DEP and DAP). It should be noted, however, that CPF measures in the New Jersey cohort study indicated very low exposure levels, which is not surprising, given that the study was initiated after home use of CPF was banned in the United States. The CCCEH and Mt. Sinai cohort studies observed statistically significant results for different biomarker-outcome associations, and there was no corroboration of any finding across studies. Thus, it would be premature to draw causal conclusions based on these inconsistent, uncorroborated findings.

ANIMAL STUDY RESULTS {#s18}
====================

Five research papers met our inclusion criteria of robust studies with data on birth weight, growth, and fetal crown-rump length after gestational and early postnatal exposure to CPF ([Table 5](#T5){ref-type="table"}). Two papers included results of two separate animal studies in mice ([@R11]) and rats ([@R7]). One of the papers was a developmental neurotoxicity study in rats ([@R22]), but because this review focuses on pup birth growth measures, only those endpoints are discussed here. Brief summaries of other general developmental and maternal toxicity are also discussed relative to the primary outcomes of interest. One additional paper found that did not meet our inclusion criteria but looked at birth and early postnatal weight ([@R17]) is also summarized in [Table 5](#T5){ref-type="table"}.

###### 

Birth outcomes and other related measures in animal CPF studies

  ----------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Reference Type of Study                                     Exposure route, duration, and dose levels (mg/kg-d)           Species and number of litters (litters/dose group)   NOEL fetal or pup birth weight                                                                                                          NOEL pup mortality or dead fetuses                                                                                         NOEL maternal toxicity                                                                                                                                                                                            NOEL maternal RBC or brain ChEI                                                                                        NOEL pup RBC or brain ChEI

  Breslin et al. 1996 Developmental                           Gavage GD6-15 0, 0.1, 3, 15                                   Fischer 344 rats\                                    0.1 mg/kg-d based on ↑fetal weight (however, authors consider NOAEL \> 15 based on historical control data)                             \>15 mg/kg-d                                                                                                               3 mg/kg-d based on clinical signs of ChEI                                                                                                                                                                         0.1 based on RBC ChEI (sacrificed GD15, 4 h after dosing)                                                              Not measured
                                                                                                                            N=24--29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Breslin et al. 1996 Reproduction                            Diet 10 wk prior to mating for 2 - generations 0, 0.1, 1, 5   Sprague-Dawley rats\                                 F1: 1 mg/kg-d based on ↓ pup weight at 5 mg/kg-d in male and female pups on Day 1 (not statistically significant).\                     F1: 1 mg/kg-d\                                                                                                             1 mg/kg-day based on, histopathology in adrenal cortex, evidence of maternal neglect, slight decreases in feed consumption during last 2 wk of lactation \>5 mg/kg-d based on clinical findings duringgestation   F1 and F2: 0.1 mg/kg-d RBC ChEI; 1 mg/kg-day brain ChEI (sacrificed 25--27 wk of age following 19-21 wk of exposure)   Not measured
                                                                                                                            F1 N=24--30\                                         F2: 0.1 mg/kg-d based on ↓ pup weight in F2 male on Day 1 (not stat sig; 1 mg/kg-d not considered by authors to be treatment related)   F2: 1 mg/kg-d (however, authors consider loss of 5 litters at 5 mg/kg-d compared to 3 in controls not treatment-related)                                                                                                                                                                                                                                                                                                                                            
                                                                                                                            F2 N=22--26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@R22] and [@R21] Developmental Neurotoxicity               Gavage GD6-LD10 0, 0.3, 1, 5                                  Sprague-Dawley rats\                                 1 mg/kg-d based on ↓ birth weight in males and females                                                                                  1 mg/kg-d pup body weight on day of birth, and pup death prior to PND 4 culling                                            1 mg/kg-d based on clinical signs of ChEI, body weight gain decreases GD1 7--20                                                                                                                                   \< 0.3 mg/kg-d RBC ChEI GD20,; 0.3 brain ChEI (sacrificed 2--4 h after dosing GD20)                                    1 mg/kg-d at GD20, (sacrificed 2--4 h after dosing)
                                                                                                                            N=20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@R15] Developmental                                        Gavage GD6-15 0, 5, 15, 25                                    Fischer 344 rats\                                    15 mg/kg-d based on ↓ fetal weight at 25 mg/kg-d                                                                                        15 mg/kg-d                                                                                                                 5 mg/kg-d based on clinical signs of ChEI (tremors) and reduced body weights                                                                                                                                      5 mg/kg-d based on brain ChEI (sacrificed GD 21, 6 d after last dose)                                                  \>25 mg/kg-d fetal brain
                                                                                                                            N=24--28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@R1] Developmental                                         Gavage GD0-20 0, 9.6, 12, 15                                  Wistar rats\                                         12 mg/kg-d based on ↓ fetal weight at 15 mg/kg-d                                                                                        12 mg/kg-d                                                                                                                 9.6 mg/kg-d based on reduced body weight gain at 1 2 mg/kg-day and clinical signs of ChEI at 15 mg/kg-d                                                                                                           Not measured                                                                                                           Not measured
                                                                                                                            N=20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@R17][^a^](#T5-FN1){ref-type="table-fn"} *Developmental*   *Gavage GD7-PND21 0, 2.5*                                     *Long Evans rats*\                                   *\>2.5 mg/kg-d, based on no effects on birth weight and body weights prior to weaning (after PND 51 f body weight in males only)*       *\>2.5 mg/kg-d*                                                                                                            *\>2.5 mg/kg-d*                                                                                                                                                                                                   *Not measured*                                                                                                         *Not measured*
                                                                                                                            *N=9--10*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@R11] Developmental (initial study)                        Gavage GD6-1 5 0,1, 10, 25                                    CF-1 Mouse 29--36                                    10 mg/kg-d based on ↓ fetal weight at 25 mg/kg-dayFetal crown-rump length NOEL=10 mg/kg-d                                               \>25 mg/kg-d                                                                                                               1 mg/kg-d based on clinical signs of ChEI                                                                                                                                                                         \<1 mg/kg-d RBC ChEI (sacrificed 5 h after last dose)                                                                  1 mg/kg-d fetal homogenate (sacrificed 5 h after last dose)

  [@R11]\                                                     Gavage GD 6-1 5 0, 0.1, 1, 10                                 CF-1 Mouse 23--30                                    \>10 mg/kg-d based on no effects on fetal weight\                                                                                       \>10 mg/kg-d                                                                                                               \>10 mg/kg-d                                                                                                                                                                                                      0.1 mg/kg-d RBC ChEI (sacrificed 5 h after last dose)                                                                  1 mg/kg-d fetal homogenate (based on non-statistically significant ChEI; sacrificed 5 h after last dose)
  Developmental (repeat study at lower doses)                                                                                                                                    Fetal crown-rump length NOEL=10 mg/kg-d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ----------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------

Note: NOAEL, no-observed-adverse-effect level; NOEL, no-observed-effect level; GD, gestation day; PND, postnatal day; ChEI cholinesterase inhibition.

This study did not meet our a *priori* inclusion criteria of n = 20. It was included because the primary focus of this study was body weight.

In the developmental toxicity study in Fischer 344 (F344) rats reported by [@R7], fetal weight was increased at all doses above controls, with statistically significant increases of 5.6% and 4.2% at 3 and 15 mg/kg-d, respectively ([Table 5](#T5){ref-type="table"}). [@R7] did not consider the increased fetal body weight to be treatment related, because there was no clear dose response and the weight rise was within the range of historical control data. There was a statistically nonsignificant elevation in fetal crown-rump length at 3 but not at 0.1 or 15 mg/kg-d, and it was not considered to be treatment related. The highest CPF dose level produced clear signs of maternal toxicity, including tremors, vaginal bleeding, excessive salivation, and decreased body weights.

In the two-generation reproduction study in Sprague-Dawley rats ([@R7]), the most relevant findings for birth outcomes were those noted at birth. No developmental effects were seen at birth except for reduced pup weight at postnatal day (PND) 1 (day of birth; not statistically significant). During lactation, there were statistically significant decreased pup weights at PND 4 and 21 and increased pup mortality in F1 pups at 5 mg/kg-d on PND 14 and 21. These changes were not seen in F2 pups, although there was an increase in pup mortality due to entire litter losses at 5 mg/kg-d that was not considered treatment-related (5 litter losses at 5 mg/kg-d vs. 3 in controls). Histologic alterations in the zona fasciculata of the adrenal gland in P1 and P2 males and females were observed at the 5-mg/kg-d dose level. These effects during lactation indicate that the 5-mg/kg-d dose level was maternally toxic. In addition, significant RBC AChE inhibition was measured in P1 and P2 adults at 1 (67--69% inhibition) and 5 (70--75% inhibition) mg/kg-d. Brain AChE inhibition of 48% was measured in P1 and P2 adults at 5 mg/kg-d. At 0.1 mg/kg-d, AChE inhibition measured in P2 males was considered spurious because there was no marked effect in either the P1 males or females or the P2 females.

[@R22] reported significantly reduced pup body weights at birth and 4 d later prior to culling in Sprague-Dawley rats exposed to 5 but not to 0.3 or 1 mg CPF/kg-d. There was increased mortality in pups (more than half cannibalized) in the high-dose (5 mg/kg-d) group with a resultant decrease in live litter size before litter size standardization on PND 4. In addition, delays in vaginal opening, pinna detachment, and preputial separation were noted at 5 mg/kg-d only, although the latter two were not statistically significant. Clinical signs of toxicity, including muscle fascilitations and decreased body weight gains, were noted in dams at 5 mg/kg-d. At GD20, there was significant (90%) brain AChE inhibition at 5 mg/kg-d, and substantial RBC ChE inhibition at 5, 1, and 0.3 mg/kg-d.

[@R15] observed effects of CPF on fetal body weight in the F344 strain of rats at 25 but not 5 and 15 mg/kg-d. Signs of developmental toxicity consisting of decreased fetal weight and viability as well as increased fetal death and early resorption, and increased fetal variations were also seen at 25 mg/kg-d but not at 5 or 15 mg/kg-d. Maternal toxicity in the form of depressed body weight and AChE inhibition was observed at 15 and 25 mg/kg-d, with significant ChE inhibition (31% and 49%, respectively) measured 6 d after the last CPF dose (PND 21).

[@R1] reported decreased fetal weight, increased fetal death, and "minor insignificant" malformations in Wistar rats at 15 mg/kg-d but not at 9.6 and 12 mg/kg-d. Clinical signs of AChE inhibition toxicity and decreased food consumption were observed in dams at 15 mg/kg-d. A significant decrease in maternal body weight gain was measured at 12 and 1 5 mg/kg-d.

In CF-1 mice exposed to 1, 10, and 25 mg/kg-d during organogenesis, fetal weight and crown-rump length were reduced only at 25 mg/kg-d ([@R11]). In addition, there were significant reductions in skeletal ossification of the skull bones, delayed ossification of the sternebrae, and unfused sternebrae in the 25 mg/kg-d fetuses, all indicating delayed growth and bone development. Maternal plasma and RBC AChE levels measured in a separate group of animals treated on gestation days (GD) 6--10 or 6--15 were significantly reduced at all dose levels when measured 5 h after the last dose, as were levels in a fetal homogenate from the 10- and 25-mg/kg-d groups. Severe maternal toxicity was seen at 25 mg/kg-d and included increased maternal deaths, severe symptoms of AChE inhibition, and reduced body weight gain. In mice exposed to 0, 0.1, 1, or 10 mg/kg/d on GD 6--15, no fetal toxicity was seen, except for a significant reduction in the incidence of delayed skull bone ossification at 1 and 10 mg/kg-d and a significant reduction in delayed ossification of the sternebrae at 10 mg/kg-d, suggesting that these animals were somewhat advanced compared to controls. These changes occurred in the presence of numerically larger size (body weight and crown-rump length) of fetuses in the two higher dose groups (statistically non significant), and are not considered toxicologically significant. Additional animals were treated at GD 6--10 or GD 6--15 and sacrificed 5 h after final dosing for AChE levels. Maternal RBC AChE and fetal homogenate AChE levels were reduced at 1 and 10 mg/kg-d.

[@R17] was a smaller study (*n* = 9--10; Long-Evans rats) that did not meet the inclusion criteria for animal studies but was evaluated because the primary focus of the study was on body weights. There was no effect of CPF on neonatal body weight prior to weaning in the one dose level (2.5 mg/kg-d) tested.

Discussion of Animal Studies In Terms of Biological Plausibility for Epidemiologic Studies {#s19}
------------------------------------------------------------------------------------------

The issue of biological plausibility for epidemiologic studies includes the question of whether the findings are consistent with comparable birth outcomes from animal studies ([Table 5](#T5){ref-type="table"}). In general, most chemicals will produce effects on fetal or pup body weight in developmental or reproductive toxicity animal studies because regulatory guidelines for toxicology studies require that the highest dose level produce some level of toxicity. Treatment-related decreases in fetal weight were generally seen at doses of 15--25 mg/kg-d (no-observed-adverse-effect level \[NOAEL\] = 10 mg/kg-d) in rats and mice following gestational exposures ([@R1]; [@R7]; [@R11]; [@R15]). Following exposures of the dams throughout both gestation and lactation, decreases in birth weight or pup weight prior to weaning occurred more consistently at doses of 5 mg/kg-d (NOAEL = 1 mg/kg-d) ([@R7]; [@R22]).

The developmental effects reported in offspring in these studies occur at doses that produce clear signs of maternal toxicity based on clinical signs and/or AChE inhibition ([Table 5](#T5){ref-type="table"}). Most of these effects are related to delayed growth and development, particularly of the skeleton, which is forming around the time of examination. The growth delays in animal studies are likely to be secondary to maternal toxicity, although potential direct effects on the fetus cannot be ruled out. During gestation, the maternal mammal is the sole source of nutrients, electrolytes, and oxygen, controls homeostatic mechanisms, regulates fluids and temperature, and provides means for the elimination of metabolic wastes (De Sesso 1987; DeSesso et al. 2009). Environmental insults that produce maternal toxicity (e.g., reductions in body weight, clinical symptoms) can lead to induction of an acute-phase response and changes in maternal metabolism that result in fetal or pup toxicity (DeSesso 1987; Keen et al. 2003a; 2003b).

Based on comparison with the NOAEL for developmental toxicity, RBC AChE inhibition in dams is a much more sensitive endpoint than effects on fetal or pup birth weight or length. The lowest dose at which RBC AChE inhibition was reported was 0.3 mg/kg-d ([@R22]), and two studies reported no RBC AChE inhibition at 0.1 mg/kg-d ([@R7]; [@R11]). Thus, 0.1 mg/kg-d may be regarded as a NOAEL for RBC AChE inhibition in dams, based on animal studies included in this review. These animal studies suggest that risk assessments based on RBC AChE inhibition in adults or offspring animals will be protective of effects on fetal weight, pup growth, and other general developmental effects. This is also true for specialized neurodevelopmental animal studies, the majority of which were conducted at doses between 1 and 5 mg/kg-d, which produce substantial RBC AChE inhibition in dams ([@R12]; [@R21]; [@R22]; [@R18]).

The Mt. Sinai cohort study evaluated the potential interaction between biomarkers of OP exposure and PON1 enzyme activity or PON 1 genotype. The animal data suggest that the overall balance between decreased PON1 detoxification and CYP450 activation/ detoxification, as well as higher rates of ChE enzyme synthesis in the preweanling rat ([@R24]; [@R28]), contributes to age-dependent and individual susceptibility to CPF toxicity ([@R31]). These experiments tend to be conducted under more extreme conditions using knockout mice (with PON1 status replacement) and higher acute doses of CPF. The extent to which these differences are of importance to humans may be dependent on exposure levels, with greater differences in susceptibility at higher acute than at low exposure levels ([@R12]). [@R10] reported that PBPK model simulations predict that PON1 Q192R polymorphism might exert the greatest impact on CPF metabolism and detoxification at dose levels greater than 0.5 mg/kg. At lower exposure levels, other esterase detoxification pathways are predicted to be capable of compensating for the interindividual differences in CPOase activity due to the PON1 Q192R polymorphism ([@R10]). Together, these animal data weaken the biological plausibility of interactions between CPF and PON1 activity on birth outcomes in human studies at lower human exposure levels.

Indeed, as discussed in greater detail earlier in this article, the evidence for PON1 enzyme activity or genotype modifying CPF effects on birth outcomes in the Mt. Sinai cohort is weak. Of the biomarkers measured, TCPy was the most specific metabolite of CPF measured, and there were no statistically significant interactions between PON1 and TCPy for any of the birth outcomes. Even though there was a statistically significant trend in head circumference across PON1 tertiles among participants with TCPy greater than the LOD (but not among those with TCPy below the LOD), the head circumference mean values for each PON1 tertile were similar for the two TCPy groups (see [Table 4](#T4){ref-type="table"}).

Estimates of exposure to pregnant women in the epidemiologic papers that meet our inclusion criteria were generally not expressed in units that easily allow direct comparisons with the animal data. [@R45] compared internal dose concentrations of CPF reported in human and animal studies and concluded that the [@R42] estimate of 2.5 pg/g in human umbilical cord blood (before January 1, 2001) is approximately 1/400 the 1-ng/g CPF level found in the blood from rat fetuses exposed at 1 mg/kg-d (animal NOAEL for fetal RBC AChE inhibition) ([@R21]). [@R45] suggested that based on this large difference in internal exposure levels, there is low biological plausibility that participants in the CCCEH study were exposed to CPF at levels that produced AChE inhibition or inhibited fetal growth. Such comparisons of animal and human exposure data are limited by differences in anatomy and physiology, including differences in respiratory, heart and metabolic rates, as well as potential differences in target tissue distribution and metabolic capacity.

[@R12] did a comprehensive review of the literature on human and animal toxicity and exposure data and estimated average daily combined CPF inhalation and dietary exposures in the CCCEH and CHAMACOS cohorts to be 0.008 and 0.007 μg/kg-d, respectively. [@R23] estimated total CPF exposures (dietary, inhalation, dermal, nondietary ingestion) among CHAMACOS pregnant women to be 1.43 to 6.73 nmol/d, which is equivalent to 0.007 to 0.031 μg/kg-d assuming a 75.8-kg pregnant female ([@R36], from NHANES). Using a physiologically based pharmacokinetic (PBPK) model, [@R20] estimated that daily doses of 0.15 μg/kg-d would result in maternal and fetal blood CPF levels within the range of the mean maternal and cord blood concentrations reported by [@R39] in the CCCEH study. Despite possible differences in physiology and metabolism, these levels in humans are several orders of magnitude below the 0.1-mg/kg-d NOAEL for laboratory animals based on RBC AChE inhibition in the developmental and reproduction studies included in this review and would not be expected to affect growth and development in humans.

SUMMARY CONCLUSIONS AND IMPLICATIONS FOR RISK ASSESSMENT {#s20}
========================================================

This review presents a comprehensive analysis that compares and contrasts results across human and animal studies which evaluated the hypothesis that CPF adversely affects birth outcomes related to fetal growth. Using guidance recommended by [@R16], an assessment was made of the evidence for and against a causal relation between possible prenatal CPF, as measured in umbilical cord plasma or serum or estimated based on levels of urinary metabolites, and these growth outcomes. Alternative explanations for the findings were considered, such as the presence of bias in the implementation of the study or during the analysis.

This review of the epidemiologic literature did not identify any strong associations exhibiting an exposure-response pattern that were observed in more than one of the four cohort studies evaluated. The adverse associations that were reported were neither particularly strong nor precise. This can be seen by general patterns of similar mean values of the birth outcome measures at different exposure levels, beta coefficients that are close to the null value of zero, and the relatively high standard errors in some of the results.

The CCCEH study is the only study that measured the parent compound CPF levels prior to cancelation of residential CPF use. Despite consistent statistically significant inverse associations between CPF in cord plasma and weight and length at birth in the CCCEH study, no marked associations were reported between CPF in air samples taken from participants in the CCCEH study during the third trimester of pregnancy and any of the birth outcomes. In addition, the statistically significant associations with CPF reported in the CCCEH studies were not corroborated by the Mt. Sinai study (TCPy, DEPs), even though there was evidence of higher residential applications of CPF among these two New York study populations.

Specifically, there were no statistically significant associations between birth length or birth weight and CPF, TCPy, or DEPs in the New Jersey, Mt. Sinai, or CHAMACOS studies. As noted previously, a majority of the cord serum CPF values was very near the limit of detection in the New Jersey Study cohort ([@R3]). No material or statistically significant associations were observed between CPF in cord blood and head circumference in the CCCEH or New Jersey cohort studies. The Mt. Sinai and CHAMACOS studies observed statistically significant associations between head circumference and DAPs, but not with DEPs or TCPy. However, these associations were in opposite directions. The Mt. Sinai study reported statistically significant trends and other group differences between PON1 activity or PON192 genotype and DEPs, DAPs, or TCPy on birth outcomes. As discussed earlier in detail, these results are inconsistent preliminary results.

Considered together, the data from the four epidemiologic cohort studies do not support a causal association between CPF exposures during pregnancy and measures of fetal growth. At present, there is insufficient scientific evidence to support the use the epidemiologic data on birth outcomes to derive a point of departure or require additional uncertainty factors for risk assessment purposes.

Challenges to future epidemiologic research on CPF exposure and fetal growth outcome measures include limited exposure among most individuals, difficulties in estimating exposure during critical periods of development, and consistency in biomarkers measured across multiple studies to allow comparisons. Although measuring the parent compound in umbilical cord blood has many clear advantages, it may be less feasible than collecting urine samples in many populations. Furthermore, it represents only one point in time. Collection of maternal blood at additional, earlier times in pregnancy would greatly enhance the information about exposure during pregnancy in future studies. Additional analyses from the existing cohorts including repeated measures of growth outcomes and patterns (e.g., height, weight, BMI), correlations among all available exposure measures (self-report, biomarker, air monitoring data), and correlations among fetal growth outcomes and neurobehavioral outcomes in infancy and early childhood may also be informative.

There is strong evidence from robust animal studies in the published literature that effects on fetal and birth weight occur at doses that are several orders of magnitude higher than those estimated in the human studies, and only at levels that produce substantial maternal RBC AChE inhibition and other signs of maternal toxicity, including reduced body weight or weight gain, or death in the most severe cases. The lowest dose level producing treatment-related decreases in fetal or birth weight is 5 mg/kg-d based on statistically nonsignificant decreases in body weight on the day of birth ([@R22]). In this study, there was substantial (\>40%) maternal RBC AChE inhibition at 0.3 mg/kg-d, the lowest dose level tested ([Figure 2](#F2){ref-type="fig"}). Indeed, using a response level of 10% RBC AChE inhibition compared to background, the U.S. EPA estimated the lower confidence bound on the benchmark dose (BMDL~10~) to be 0.03 mg/kg-d in rat dams following GD6-20 exposures ([@R37]). Thus, based on consideration of both the epidemiologic and animal data, RBC AChE inhibition is a more sensitive endpoint for risk assessment than somatic developmental effects reviewed in this article.

![Comparison of NOAELs and LOAELs for fetal weight, birth weight, and maternal toxicity from animal studies with human exposure estimates. Human exposure estimates were calculated from McCone et al. (2007) based on CHAMACOS study. [@R23] estimated total CPF exposures (dietary, inhalation, dermal, nondietary ingestion) among pregnant women in the CHAMACOS cohort to be 1.43 to 6.73 nmol/d, which is equivalent to 0.007 to 0.031 μg/kg-d, assuming a 75.8-kg pregnant female ([@R36], from NHANES). [@R20] estimated exposures based on umbilical cord blood levels from the CCCEH cohort ([@R39]). The NOAEL of 1 mg/kg-d for pup birth weight is based on non-statistically significant treatment-related decreases at 5 mg/kg-d Breslin et al. (2006) and [@R22] (see [Table 5](#T5){ref-type="table"}). The LOAEL of 5 mg/kg-d for maternal toxicity (e.g., tremors) and pup death is based on [@R22]. The NOAEL of 12 mg/kg-d for fetal birth weight is the highest NOAEL for effects in multiple studies as summarized in [Table 5](#T5){ref-type="table"}.](uteb15_281_f2){#F2}
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